Why Dynavax Stock Zoomed Higher Today
Dynavax Technologies (NASDAQ: DVAX), a biotech considered by some to be a coronavirus stock, outpaced the broader market on Wednesday. The company's shares rose by 5.6%, on the back of a significant price-target increase from an analyst.
That analyst is Edward White of H.C. Wainwright, who this morning lifted his price target on the stock to $28 from the previous $23, while maintaining his buy recommendation.
Image source: Getty Images.
Source Fool.com